Unicycive Therapeutics UNCY
NASDAQ UNCY
$3.63 -0.15 (-3.97%)
As of: Nov 12, 2026 · 10:59 AM EST

Unicycive Therapeutics (UNCY) Gains (Losses) on Sale of Assets & Investments (2026)

Updated

Analysis

Unicycive Therapeutics (UNCY) Gains (Losses) on Sale of Assets & Investments (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Gains on Sales (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn -
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn -
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn -
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 Unicycive Therapeutics 101.95 Mn -98.02 Mn - -29,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -29,000.00
Mar 31, 2026 -1,000.00
API Access

Unicycive Therapeutics Gains (Losses) on Sale of Assets & Investments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=UNCY&period=max&api_key=YOUR_API_KEY